<DOC>
	<DOCNO>NCT00109889</DOCNO>
	<brief_summary>RATIONALE : Diagnostic procedure , magnetic resonance imaging ( MRI ) fludeoxyglucose F 18 positron emission tomography ( ^18FDG-PET ) may help diagnose solitary plasmacytoma . PURPOSE : This clinical trial study MRI ^18FDG-PET see well work diagnose patient solitary plasmacytoma .</brief_summary>
	<brief_title>S0340 MRI Fludeoxyglucose F18 PET Diagnosing Solitary Plasmacytoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine proportion patient misclassified true solitary plasmacytoma MRI whole-body fludeoxyglucose F 18 positron emission tomography supplement image skeletal survey . - Determine feasibility accrue patient study . - Determine , preliminarily , biological correlate prognostic group may relate progression symptomatic disease patient undergo imaging procedure . - Correlate germline genetic polymorphism overall clinical course patient undergo imaging procedure . OUTLINE : This multicenter study . Within 28 day study entry , patient undergo gadolinium MRI head , spine , pelvis ( site , indicate ) . Patients receive fludeoxyglucose F 18 IV follow 90 minute later whole-body positron emission tomography ( ^18FDG-PET ) OR whole-body CT scan/PET . Patients confirm diagnosis solitary plasmacytoma undergo MRI ^18FDG-PET 1 year annually 10 year absence disease progression ( i.e. , change status solitary plasmacytoma active myeloma biopsy confirm stage IB high multiple myeloma ) . After completion study procedure , patient follow every 6 month 10 year . PROJECTED ACCRUAL : A total 110 patient accrue study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm solitary plasmacytoma 1 follow type : Solitary bone plasmacytoma Extraosseus solitary plasmacytoma Bone marrow plasmacytosis &lt; 10 % within past 4 week Low serum and/or urine Mprotein meeting ≥ 1 follow criterion : Serum IgG &lt; 3.5 g/dL Serum IgA &lt; 2.0 g/dL Urine Mprotein ( kappa lambda ) &lt; 1.0 g/24 hour No lytic lesion skeletal survey single lesion associate solitary plasmacytoma within past 4 week PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 02 Life expectancy Not specify Hematopoietic Hemoglobin ≥ 10 g/dL* AND/OR No hemoglobin 2 g/dL &lt; low limit normal* ( LLN ) NOTE : *Patients history hemoglobin &lt; 10 g/dL AND/OR &lt; 2 g/dL &lt; LLN correct improved epoetin alfa require continued treatment epoetin alfa eligible Hepatic Not specify Renal Calcium ≤ 10.5 mg/dL OR Calcium normal Creatinine ≤ 2 mg/dL Other No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix breast , stage I II cancer currently complete remission PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy No prior highdose steroid except relieve neurological compromise Radiotherapy Prior localize radiotherapy myeloma allow Concurrent radiotherapy allow Surgery Prior surgery myeloma allow Other No prior therapy myeloma Concurrent enrollment protocol SWOGS0309 ( Myeloma Specimen Repository ) allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>extramedullary plasmacytoma</keyword>
	<keyword>isolated plasmacytoma bone</keyword>
</DOC>